Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 10, 2011Clinical Cancer ResearchOpen Access

Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

Hagop M. KantarjianHagop M. KantarjianThe University of Texas MD Anderson Cancer CenterMichele BaccaraniMichele BaccaraniUniversity of BergamoElias JabbourElias JabbourLiechtenstein Institute

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kantarjian et al. (2011) studied this question.

synapsesocial.com/papers/6a1ea55899b676b6b9af1e6bhttps://doi.org/10.1158/1078-0432.ccr-10-2922
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)2008 · 71 citations
  2. 2The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.2009 · 13 citations
  3. 324 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).2009 · 34 citations
  4. 4Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia2006 · 3,516 citations
  5. 5ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)2010 · 43 citations